Myeloma

Genetic test helps identify risk for more aggressive disease, improving myeloma treatment

By

New research has identified as few as nine genetic features would need to be tested to identify high-risk patients who might benefit from intensive myeloma treatment.

ASCO: Elotuzumab demonstrates benefit in multiple myeloma

ASCO: Elotuzumab demonstrates benefit in multiple myeloma

Survival gains observed when elotuzumab was added to treatment.

ASH: Carfilzomib increases survival in relapsed multiple myeloma

ASH: Carfilzomib increases survival in relapsed multiple myeloma

Improved progression-free survival in relapsed multiple myeloma has been seen with the addition of carfilzomib to lenalidomide and dexamethasone therapy.

New potential therapeutic agents for myeloma are on the horizon

New potential therapeutic agents for myeloma are on the horizon

Recent therapeutic progress has improved outcomes for patients with myeloma; however, the complex biology of this disease continues to challenge treatment.

New myeloma treatment options promising

New myeloma treatment options promising

New multiple myeloma treatment options have shown promise for patients aged 65 years and younger and for newly diagnosed individuals ineligible for stem-cell transplantation, according to two studies.

Treatment effective for smoldering multiple myeloma

Treatment effective for smoldering multiple myeloma

Lenalidomide plus dexamethasone delays progression, improves survival versus observation

Kyprolis approved for multiple myeloma

Kyprolis approved for multiple myeloma

Carfilzomib is approved for people who have been treated with at least two other therapies.

Bortezomib ups response, survival in multiple myeloma

Bortezomib ups response, survival in multiple myeloma

Bortezomib induction/maintenance up complete response, progression-free, and overall survival rates.

Coping with Multiple Myeloma

Coping with Multiple Myeloma

These tips can help patients with multiple myeloma learn more about how to cope with the disease.

Lenalidomide maintenance beneficial in multiple myeloma

Lenalidomide maintenance beneficial in multiple myeloma

Three studies show benefit of lenalidomide, including after induction therapy or stem-cell transplant.

Blood cancers often require termination of early pregnancy

By

The urgent need for treatment may require a woman with a hematologic cancer to end an early-stage pregnancy, but not necessarily a later-stage one.

Multiple Myeloma: Finding Resources and Support

Multiple Myeloma: Finding Resources and Support

This fact sheet reviews a number of resources available to patients coping with multiple myeloma, from the health care team to in the community.

Using ESAs in patients with cancer-related anemia

Using ESAs in patients with cancer-related anemia

Although the risks of erythropoietin-stimulating agents can outweigh the benefits, select patients may benefit.

Multiple Myeloma: Making the Most of Your Medical Appointments

Multiple Myeloma: Making the Most of Your Medical Appointments

Many people see their cancer care as a collaboration. This fact sheet provides tips for patients with multiple myeloma for improving communication with providers during office visits.

Overall cancer mortality rates decrease, but incidence of some cancers increases

Overall, cancer incidence rates fell approximately 1% annually and overall death rates decreased by an average of 1.6% annually between 2003 and 2007.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs